| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Carcinoma, Non-Small-Cell Lung | 12 | 2019 | 896 | 2.81 | Why? |
| ErbB Receptors | 13 | 2019 | 320 | 2.55 | Why? |
| Protein Kinase Inhibitors | 7 | 2019 | 1585 | 2.00 | Why? |
| Lung Neoplasms | 18 | 2019 | 3228 | 1.93 | Why? |
| Mycobacterium avium Complex | 3 | 2018 | 61 | 1.52 | Why? |
| Taiwan | 29 | 2021 | 2556 | 1.50 | Why? |
| Mycobacterium avium-intracellulare Infection | 3 | 2018 | 59 | 1.49 | Why? |
| Lung Diseases | 6 | 2019 | 2361 | 1.38 | Why? |
| Pulmonary Disease, Chronic Obstructive | 9 | 2019 | 3832 | 1.25 | Why? |
| Quinazolines | 2 | 2017 | 126 | 1.24 | Why? |
| Image-Guided Biopsy | 2 | 2017 | 185 | 1.22 | Why? |
| Erlotinib Hydrochloride | 3 | 2019 | 48 | 1.08 | Why? |
| B7-H1 Antigen | 2 | 2017 | 541 | 1.01 | Why? |
| Antineoplastic Agents | 7 | 2018 | 3550 | 0.86 | Why? |
| Placenta Growth Factor | 2 | 2018 | 93 | 0.85 | Why? |
| Liver Neoplasms | 4 | 2019 | 1666 | 0.80 | Why? |
| Acetylcarnitine | 1 | 2019 | 7 | 0.79 | Why? |
| Mycobacterium Infections, Nontuberculous | 2 | 2019 | 167 | 0.77 | Why? |
| Bronchoscopy | 2 | 2017 | 991 | 0.76 | Why? |
| Xeroderma Pigmentosum Group D Protein | 1 | 2018 | 3 | 0.75 | Why? |
| Matrix Metalloproteinase 12 | 1 | 2018 | 17 | 0.74 | Why? |
| Receptor, PAR-1 | 1 | 2018 | 24 | 0.73 | Why? |
| Insurance Claim Review | 1 | 2018 | 108 | 0.73 | Why? |
| Fluticasone-Salmeterol Drug Combination | 1 | 2017 | 10 | 0.72 | Why? |
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2017 | 7 | 0.72 | Why? |
| Drug Resistance, Neoplasm | 2 | 2019 | 447 | 0.71 | Why? |
| Endonucleases | 1 | 2018 | 68 | 0.70 | Why? |
| Interleukin-23 | 1 | 2018 | 64 | 0.70 | Why? |
| Leptospirosis | 1 | 2018 | 103 | 0.69 | Why? |
| Multiple Pulmonary Nodules | 1 | 2018 | 115 | 0.67 | Why? |
| Ventilator Weaning | 2 | 2019 | 536 | 0.64 | Why? |
| International Classification of Diseases | 1 | 2018 | 265 | 0.60 | Why? |
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 142 | 0.59 | Why? |
| DNA-Binding Proteins | 1 | 2018 | 469 | 0.56 | Why? |
| Virus Activation | 1 | 2019 | 480 | 0.55 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.55 | Why? |
| Cholesterol | 1 | 2018 | 660 | 0.54 | Why? |
| Pulmonary Edema | 1 | 2018 | 430 | 0.52 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.51 | Why? |
| Pneumonia | 5 | 2020 | 5652 | 0.51 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.50 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.46 | Why? |
| Th17 Cells | 1 | 2017 | 657 | 0.46 | Why? |
| Bronchodilator Agents | 1 | 2017 | 444 | 0.46 | Why? |
| Metformin | 1 | 2019 | 640 | 0.46 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.46 | Why? |
| Multiple Organ Failure | 2 | 2019 | 1724 | 0.44 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.43 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2017 | 698 | 0.43 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.41 | Why? |
| Up-Regulation | 1 | 2018 | 2249 | 0.40 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.40 | Why? |
| Subclavian Artery | 1 | 2009 | 21 | 0.39 | Why? |
| Diverticulum | 1 | 2009 | 28 | 0.39 | Why? |
| Mutation | 12 | 2019 | 12376 | 0.38 | Why? |
| Abnormalities, Multiple | 1 | 2009 | 75 | 0.38 | Why? |
| Vascular Malformations | 1 | 2009 | 52 | 0.38 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.37 | Why? |
| Disease Progression | 6 | 2019 | 13580 | 0.36 | Why? |
| Aged | 47 | 2021 | 215776 | 0.36 | Why? |
| Blood Pressure | 2 | 2018 | 2198 | 0.35 | Why? |
| Middle Aged | 51 | 2021 | 270681 | 0.34 | Why? |
| Apoptosis | 2 | 2018 | 2335 | 0.34 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.33 | Why? |
| Brain Neoplasms | 3 | 2019 | 669 | 0.32 | Why? |
| Retreatment | 2 | 2017 | 186 | 0.32 | Why? |
| Proportional Hazards Models | 6 | 2019 | 6543 | 0.32 | Why? |
| Kaplan-Meier Estimate | 6 | 2018 | 4260 | 0.32 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.32 | Why? |
| Male | 55 | 2021 | 367725 | 0.32 | Why? |
| Adenocarcinoma | 3 | 2018 | 651 | 0.31 | Why? |
| Hypoglycemic Agents | 1 | 2019 | 2165 | 0.31 | Why? |
| Aorta | 1 | 2009 | 355 | 0.31 | Why? |
| Female | 56 | 2021 | 380317 | 0.30 | Why? |
| Retrospective Studies | 27 | 2021 | 105322 | 0.30 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.30 | Why? |
| Aged, 80 and over | 25 | 2020 | 88759 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.29 | Why? |
| Lymphocytes | 2 | 2021 | 3056 | 0.29 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.28 | Why? |
| Propensity Score | 3 | 2017 | 2690 | 0.27 | Why? |
| Tuberculosis | 2 | 2017 | 2895 | 0.27 | Why? |
| Mycobacterium tuberculosis | 3 | 2017 | 1164 | 0.26 | Why? |
| Case-Control Studies | 9 | 2020 | 17671 | 0.26 | Why? |
| Prognosis | 11 | 2021 | 32490 | 0.25 | Why? |
| Deglutition Disorders | 1 | 2009 | 481 | 0.25 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2017 | 1969 | 0.24 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| Databases, Factual | 6 | 2018 | 6248 | 0.22 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.22 | Why? |
| Pemetrexed | 2 | 2018 | 32 | 0.22 | Why? |
| National Health Programs | 2 | 2018 | 807 | 0.22 | Why? |
| Humans | 66 | 2021 | 930598 | 0.21 | Why? |
| Drug Resistance, Bacterial | 4 | 2017 | 1414 | 0.21 | Why? |
| Respiratory Insufficiency | 2 | 2019 | 7301 | 0.21 | Why? |
| Survival Analysis | 6 | 2019 | 7592 | 0.21 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.20 | Why? |
| Disease-Free Survival | 4 | 2017 | 1654 | 0.20 | Why? |
| Anti-Bacterial Agents | 6 | 2018 | 10083 | 0.20 | Why? |
| Carnitine | 1 | 2019 | 47 | 0.19 | Why? |
| Kidney Tubules, Proximal | 1 | 2020 | 178 | 0.19 | Why? |
| Logistic Models | 6 | 2020 | 9089 | 0.19 | Why? |
| Early Growth Response Protein 1 | 1 | 2018 | 12 | 0.19 | Why? |
| Lung | 6 | 2018 | 31049 | 0.19 | Why? |
| Caspase 9 | 1 | 2018 | 38 | 0.19 | Why? |
| Blast Injuries | 1 | 2018 | 20 | 0.19 | Why? |
| X-ray Repair Cross Complementing Protein 1 | 1 | 2018 | 6 | 0.19 | Why? |
| Platinum Compounds | 1 | 2018 | 20 | 0.18 | Why? |
| Oncogene Proteins, Fusion | 1 | 2018 | 52 | 0.18 | Why? |
| Mandibular Advancement | 1 | 2017 | 5 | 0.18 | Why? |
| Pleural Effusion, Malignant | 1 | 2018 | 37 | 0.18 | Why? |
| Agglutination Tests | 1 | 2018 | 124 | 0.18 | Why? |
| Hematuria | 1 | 2020 | 284 | 0.18 | Why? |
| TRPM Cation Channels | 1 | 2017 | 25 | 0.18 | Why? |
| Burkholderia cenocepacia | 1 | 2017 | 10 | 0.18 | Why? |
| Tuberculosis, Urogenital | 1 | 2017 | 12 | 0.18 | Why? |
| Caspase 3 | 1 | 2018 | 218 | 0.17 | Why? |
| HLA-DP beta-Chains | 1 | 2017 | 8 | 0.17 | Why? |
| Butyrophilins | 1 | 2017 | 4 | 0.17 | Why? |
| Respiration, Artificial | 3 | 2017 | 22116 | 0.17 | Why? |
| Time Factors | 8 | 2019 | 31397 | 0.17 | Why? |
| Burkholderia Infections | 1 | 2017 | 33 | 0.17 | Why? |
| Bone Nails | 1 | 2017 | 18 | 0.17 | Why? |
| Gain of Function Mutation | 1 | 2017 | 54 | 0.17 | Why? |
| Mycobacterium avium | 1 | 2016 | 10 | 0.17 | Why? |
| Antigens, Nuclear | 1 | 2017 | 32 | 0.17 | Why? |
| Lymphocyte Activation | 2 | 2018 | 2742 | 0.17 | Why? |
| Humeral Fractures | 1 | 2017 | 25 | 0.17 | Why? |
| Protein-Tyrosine Kinases | 1 | 2018 | 158 | 0.17 | Why? |
| Hepatitis B Surface Antigens | 1 | 2019 | 305 | 0.17 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.17 | Why? |
| Mycobacterium abscessus | 1 | 2016 | 31 | 0.17 | Why? |
| Sleep Apnea, Obstructive | 2 | 2017 | 668 | 0.17 | Why? |
| Sulfones | 1 | 2017 | 66 | 0.16 | Why? |
| THP-1 Cells | 1 | 2018 | 374 | 0.16 | Why? |
| Small Cell Lung Carcinoma | 1 | 2018 | 133 | 0.16 | Why? |
| Cohort Studies | 7 | 2020 | 36005 | 0.16 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.16 | Why? |
| Follow-Up Studies | 4 | 2019 | 17020 | 0.16 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.16 | Why? |
| Bacteremia | 2 | 2017 | 1372 | 0.16 | Why? |
| Proto-Oncogene Proteins | 1 | 2018 | 340 | 0.15 | Why? |
| Interferon-gamma Release Tests | 1 | 2018 | 253 | 0.15 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 179 | 0.15 | Why? |
| Doxycycline | 1 | 2018 | 307 | 0.15 | Why? |
| Cold Temperature | 1 | 2017 | 260 | 0.15 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.15 | Why? |
| Treatment Failure | 2 | 2019 | 2106 | 0.15 | Why? |
| Adult | 29 | 2021 | 244371 | 0.15 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.15 | Why? |
| Symptom Assessment | 2 | 2020 | 4967 | 0.15 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.14 | Why? |
| Fracture Fixation | 1 | 2017 | 128 | 0.14 | Why? |
| Factor Analysis, Statistical | 1 | 2017 | 538 | 0.14 | Why? |
| Early Medical Intervention | 1 | 2018 | 487 | 0.14 | Why? |
| Sleep Apnea Syndromes | 1 | 2018 | 282 | 0.14 | Why? |
| Radiosurgery | 1 | 2017 | 249 | 0.14 | Why? |
| Macrophage Activation | 1 | 2017 | 315 | 0.14 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.14 | Why? |
| Nerve Tissue Proteins | 1 | 2017 | 319 | 0.14 | Why? |
| Embryoid Bodies | 1 | 2013 | 9 | 0.14 | Why? |
| Transcription Factors | 2 | 2017 | 784 | 0.14 | Why? |
| Critical Care | 2 | 2018 | 14081 | 0.14 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.13 | Why? |
| ROC Curve | 4 | 2020 | 6024 | 0.13 | Why? |
| Latent Tuberculosis | 1 | 2018 | 324 | 0.13 | Why? |
| Adrenergic beta-Antagonists | 1 | 2017 | 465 | 0.13 | Why? |
| Embryonic Stem Cells | 1 | 2013 | 66 | 0.13 | Why? |
| Comorbidity | 7 | 2021 | 34796 | 0.13 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.12 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.12 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 520 | 0.12 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2016 | 604 | 0.12 | Why? |
| Ultrasonography | 3 | 2017 | 4409 | 0.12 | Why? |
| Treatment Outcome | 9 | 2019 | 51732 | 0.12 | Why? |
| Continuous Positive Airway Pressure | 2 | 2018 | 1187 | 0.11 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.11 | Why? |
| Diagnostic Imaging | 1 | 2020 | 1044 | 0.11 | Why? |
| Burns | 1 | 2018 | 466 | 0.11 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.11 | Why? |
| Predictive Value of Tests | 4 | 2020 | 9537 | 0.11 | Why? |
| Administration, Inhalation | 1 | 2017 | 1647 | 0.11 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.11 | Why? |
| Odds Ratio | 3 | 2017 | 5861 | 0.11 | Why? |
| Radiography | 1 | 2018 | 1576 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.10 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1573 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2019 | 902 | 0.10 | Why? |
| Acute Kidney Injury | 2 | 2021 | 5762 | 0.10 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.10 | Why? |
| Nasal Mucosa | 1 | 2017 | 1218 | 0.10 | Why? |
| Age Factors | 3 | 2020 | 21039 | 0.10 | Why? |
| Neoplasms | 2 | 2021 | 17251 | 0.10 | Why? |
| Aortography | 1 | 2009 | 60 | 0.10 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.10 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.09 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.09 | Why? |
| Flavonoids | 1 | 2013 | 492 | 0.09 | Why? |
| Intensive Care Units | 4 | 2019 | 29594 | 0.09 | Why? |
| Homes for the Aged | 1 | 2018 | 1071 | 0.09 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.09 | Why? |
| Tuberculosis, Pulmonary | 1 | 2018 | 1171 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| DNA Gyrase | 2 | 2017 | 30 | 0.09 | Why? |
| Terminal Care | 1 | 2018 | 928 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2017 | 973 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.09 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.08 | Why? |
| Severity of Illness Index | 5 | 2018 | 48226 | 0.08 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.08 | Why? |
| Hospital Information Systems | 1 | 2008 | 115 | 0.08 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.08 | Why? |
| Exons | 2 | 2017 | 158 | 0.08 | Why? |
| Myocytes, Cardiac | 1 | 2013 | 804 | 0.08 | Why? |
| Mortality | 3 | 2020 | 7132 | 0.08 | Why? |
| Smoking | 2 | 2017 | 3358 | 0.08 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.08 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| Tomography, X-Ray Computed | 4 | 2018 | 25144 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.08 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.08 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.08 | Why? |
| Cytokines | 2 | 2019 | 15010 | 0.07 | Why? |
| Hospitalization | 7 | 2020 | 54280 | 0.07 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.07 | Why? |
| DNA Mutational Analysis | 2 | 2018 | 581 | 0.07 | Why? |
| Epithelial Cells | 1 | 2017 | 3508 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.07 | Why? |
| Severe Acute Respiratory Syndrome | 3 | 2021 | 12361 | 0.07 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.07 | Why? |
| Microbial Sensitivity Tests | 3 | 2017 | 2886 | 0.07 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.07 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.07 | Why? |
| Mice | 3 | 2018 | 21357 | 0.06 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2017 | 449 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Caregivers | 1 | 2018 | 3112 | 0.06 | Why? |
| DNA, Bacterial | 2 | 2017 | 835 | 0.06 | Why? |
| Tertiary Care Centers | 2 | 2017 | 8248 | 0.06 | Why? |
| Young Adult | 6 | 2018 | 93724 | 0.06 | Why? |
| Risk Assessment | 4 | 2020 | 25439 | 0.06 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2019 | 3892 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.06 | Why? |
| Glycosuria | 1 | 2020 | 11 | 0.06 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.05 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2018 | 3633 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.05 | Why? |
| Body Surface Area | 1 | 2018 | 50 | 0.05 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Tumor Cells, Cultured | 1 | 2018 | 254 | 0.05 | Why? |
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 37 | 0.05 | Why? |
| Mice, SCID | 1 | 2018 | 225 | 0.05 | Why? |
| Sensory System Agents | 1 | 2017 | 1 | 0.05 | Why? |
| Rec A Recombinases | 1 | 2017 | 5 | 0.05 | Why? |
| Explosions | 1 | 2018 | 42 | 0.05 | Why? |
| Reserpine | 1 | 2017 | 3 | 0.05 | Why? |
| Menthol | 1 | 2017 | 6 | 0.05 | Why? |
| Acrylamides | 1 | 2017 | 40 | 0.05 | Why? |
| Keratin-14 | 1 | 2017 | 11 | 0.04 | Why? |
| Administrative Claims, Healthcare | 1 | 2018 | 124 | 0.04 | Why? |
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2017 | 4 | 0.04 | Why? |
| Sequence Analysis, DNA | 2 | 2017 | 2830 | 0.04 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2018 | 274 | 0.04 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Biological Transport, Active | 1 | 2017 | 46 | 0.04 | Why? |
| External Fixators | 1 | 2017 | 3 | 0.04 | Why? |
| DNA, Ribosomal Spacer | 1 | 2017 | 49 | 0.04 | Why? |
| Verapamil | 1 | 2017 | 46 | 0.04 | Why? |
| Open Fracture Reduction | 1 | 2017 | 28 | 0.04 | Why? |
| DNA, Ribosomal | 1 | 2017 | 112 | 0.04 | Why? |
| Mucin 5AC | 1 | 2017 | 46 | 0.04 | Why? |
| Thyroid Nuclear Factor 1 | 1 | 2016 | 12 | 0.04 | Why? |
| Aniline Compounds | 1 | 2017 | 120 | 0.04 | Why? |
| Elbow Joint | 1 | 2017 | 27 | 0.04 | Why? |
| Keratin-18 | 1 | 2017 | 114 | 0.04 | Why? |
| Heart Arrest | 1 | 2008 | 1239 | 0.04 | Why? |
| Carboplatin | 1 | 2017 | 76 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Germ-Line Mutation | 1 | 2017 | 86 | 0.04 | Why? |
| Vital Capacity | 1 | 2018 | 399 | 0.04 | Why? |
| Polyesters | 1 | 2017 | 94 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2017 | 281 | 0.04 | Why? |
| Epithelial-Mesenchymal Transition | 1 | 2018 | 242 | 0.04 | Why? |
| Hyponatremia | 1 | 2020 | 371 | 0.04 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2017 | 239 | 0.04 | Why? |
| Mass Casualty Incidents | 1 | 2018 | 166 | 0.04 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2017 | 273 | 0.04 | Why? |
| Cisplatin | 1 | 2017 | 209 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Fracture Fixation, Internal | 1 | 2017 | 188 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Salvage Therapy | 1 | 2017 | 417 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Creatinine | 1 | 2021 | 1443 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Absorbable Implants | 1 | 2017 | 191 | 0.03 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.03 | Why? |
| Cells, Cultured | 2 | 2017 | 5835 | 0.03 | Why? |
| Nuclear Proteins | 1 | 2016 | 321 | 0.03 | Why? |
| Leukocytes | 1 | 2021 | 1046 | 0.03 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.03 | Why? |
| Animals | 3 | 2018 | 78931 | 0.03 | Why? |
| China | 4 | 2021 | 50654 | 0.03 | Why? |
| Catheter-Related Infections | 1 | 2017 | 381 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Bronchiectasis | 1 | 2016 | 312 | 0.03 | Why? |
| Magnetic Resonance Imaging | 1 | 2009 | 6551 | 0.03 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
| Polysomnography | 1 | 2013 | 296 | 0.03 | Why? |
| Myocardial Ischemia | 1 | 2018 | 781 | 0.03 | Why? |
| Demography | 1 | 2018 | 1660 | 0.03 | Why? |
| Pyridines | 1 | 2017 | 680 | 0.03 | Why? |
| SARS Virus | 2 | 2005 | 13021 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Genome-Wide Association Study | 1 | 2017 | 1648 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Sex Characteristics | 1 | 2017 | 1120 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 11367 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Cell Differentiation | 1 | 2013 | 1338 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.02 | Why? |
| Pyrazines | 1 | 2017 | 1783 | 0.02 | Why? |
| Ventilators, Mechanical | 1 | 2018 | 2193 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2018 | 3228 | 0.02 | Why? |
| Pharynx | 1 | 2013 | 1544 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.02 | Why? |
| Cause of Death | 1 | 2018 | 4823 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.01 | Why? |
| Risk Management | 1 | 2008 | 1044 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Body Mass Index | 1 | 2013 | 4306 | 0.01 | Why? |
| Adaptation, Psychological | 1 | 2018 | 4996 | 0.01 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2013 | 11304 | 0.01 | Why? |
| Academic Medical Centers | 1 | 2008 | 3088 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Referral and Consultation | 1 | 2008 | 4816 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2005 | 9893 | 0.01 | Why? |
| Communicable Diseases, Emerging | 1 | 2004 | 2523 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2005 | 9091 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |